Skip to main content

Politics Health Canada approves non-prescription naloxone nasal spray

Health Minister Jane Philpott has authorized naloxone nasal spray for non-prescription use.

Hand-out/Adapt Pharma

Health Minister Jane Philpott has authorized naloxone nasal spray for non-prescription use to help prevent deaths from opioid overdoses.

Naloxone, sold under the brand name Narcan, can reverse the effects of an opioid overdose if used promptly.

Monday's move follows an interim order by Philpott in July that allowed naloxone nasal spray to be imported from the U.S. Only the injectable version of the drug had been approved in Canada.

Story continues below advertisement

The nasal spray is considered easier to administer than the injectable version, especially for those who aren't trained health-care professionals.

Health Canada says the nasal spray's manufacturer can now take the necessary steps to officially bring the product to market in Canada.

Until then, the U.S.-approved product will continue to be available in Canada to avoid interruption in supply.

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Discussion loading ...

Cannabis pro newsletter